Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 30OTHER 15NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lymphoma, Large-Cell, Anaplastic 3Neuroblastoma 2Carcinoma, Non-Small-Cell Lung 2Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma, Alveolar 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Granuloma, Plasma Cell 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 33Paclitaxel 28Radiotherapy 23Cisplatin 23Docetaxel 18Gemcitabine 14Pemetrexed 13Radiosurgery 9Bevacizumab 9Magnetic Resonance Spectroscopy 7Etoposide 7Ramucirumab 6Erlotinib Hydrochloride 6Cetuximab 6Specimen Handling 5Gene Expression Profiling 5durvalumab 4cediranib 4Vinorelbine 4Polymerase Chain Reaction 4Amplified Fragment Length Polymorphism Analysis 4pembrolizumab 3cemiplimab 3Watchful Waiting 3Taxes 3Surgical Procedures, Operative 3Radiotherapy, Conformal 3Psychiatric Rehabilitation 3Neoadjuvant Therapy 3Fluorodeoxyglucose F18 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Carcinoma, Non-Small-Cell Lung × Crizotinib × Clear all
NCT02201992 2025-12-19

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
166 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02134912 2020-02-20

S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

SWOG Cancer Research Network

Phase 2 Terminated
1 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡